IMNMImmunome Inc.
Pharmaceutical Preparations
- Revenue
- $7M
- 23% YoY
- Operating margin
- -3228.8%
- 4.5% YoY
- EBITDA
- −$222M
- 27% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$217M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired370% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $14M | $9M | $7M | 23% |
| Operating income | −$25M | −$37M | −$110M | −$306M | −$224M | 27% |
| Net income | −$25M | −$37M | −$107M | −$293M | −$212M | 28% |
| Operating cash flow | −$18M | −$29M | −$8M | −$111M | −$191M | 72% |
| Capex | $79K | $248K | $831K | $7M | $10M | 35% |
| Stock-based comp | $3M | $5M | $6M | $16M | $26M | 63% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $334K · 1
- Net
- −$334K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | $28M | 201 | — |
| FY2024 | $9M | $8M | 99 | — |